Jiangsu HengRui Medicine Co., Ltd.
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Camrelizumab、Rivoceranib
Camrelizumab
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 251 participants |
Masking: | None (Open Label) |
Masking Description: | Camrelizumab Plus Rivoceranib (Apatinib) compared with Camrelizumab |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-Label, Multi-Center, Phase 2 Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation |
Actual Study Start Date : | September 1, 2022 |
Estimated Primary Completion Date : | April 30, 2026 |
Estimated Study Completion Date : | April 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment group Camrelizumab Plus Rivoceranib (Apatinib) |
Drug: Camrelizumab、Rivoceranib |
Active Comparator: Control group Camrelizumab |
Drug: Camrelizumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai, China, 200032